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Background: In schizophrenia pathophysiology, increasing evidence point to a critical role of redox dysregulation / oxidative stress leading to impairments of fast spiking parvalbumine interneurons (PVI) which are essential for gamma oscillations generation, thus contributing to cognitive deficit. Animal models of psychosis including the ketamine/PCP, NHVL, DISC1, GluN1-KO and gclm KO models converge in showing increase in oxidative stress markers and PVI impairment in prefrontal cortex. PVIs surrounded by perineuronal net (PNN), also express matrix metalloproteases (MMPs) which are induced in inflammatory and activated in oxidative stress conditions, potentially leading to PNN degradation. Evidence also indicates the implication of immune dysregulation in schizophrenia, highlighted by anomalies in peripheral immune cells and association with immune-related genes in genome-wide association studies. In a transgenic mouse model with glutathione (GSH) synthesis deficit (*gclm* KO), we investigate the interaction between oxidative stress and neuroinflammation in early development and its effect on PVI/PNN circuitry in adulthood.

Methods: In gclm KO versus WT mice, we compared by immunohistochemistry the expression of oxidative stress markers (8-oxoDG), microglia markers (Iba1, CD11b and CD68), Receptor for Advanced Glycation End-product (RAGE) and the metalloprotease MMP9 in anterior cingulate cortex (ACC) at peripuberty (P40) and adulthood (P90). Mice were treated with dopamine reuptake inhibitor (GBR12909; P10-P20) to mimic environmental insults which induce additional oxidative stress.

Results: GBR treatment in young mice led to increased 8-oxoDG and microglia activation, decreased PVI+ and PV-PNN+-immunoreactivity in adult *gclm* KO, showing a tight interaction between the oxidative stress and pro-inflammatory state and a long-term effect of an early oxidative insult. Microglia activation was more pronounced at peripubertal stage compared to adulthood, suggesting a developmental vulnerability in *gclm* KO. We explored the role of RAGE, which is activated by ligands produced by oxidative stress, and found increased RAGE shedding in neurons as well as increased MMP9-IR in *gclm* KO at P40. Interestingly, a specific inhibitor of MMP9 prevented RAGE shedding and microglia activation in the ACC of P40 *gclm* KO, demonstrating the critical involvement of MMP9 in this process. MMP9 inhibition might thus also limit oxidative stress and PVI/PNN deficit.

Conclusion: RAGE shedding via MMP9 is a key regulatory mechanism by which oxidative stress interacts with neuroinflammatory condition. This pathological interaction in early development might be a potential trigger of adulthood PVI and PNN impairments observed in schizophrenia.
